Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of icarisid I type compound for preparing IDO inhibitor

A technology of icariin and compound, which is applied in the field of preparing IDO inhibitor and icariin class I compound

Inactive Publication Date: 2019-02-22
FOSHAN GOLDEN HEALTH TECH CO LTD
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] Therefore, IDO inhibitors have broad application prospects as drugs, but so far no suitable IDO inhibitors can be marketed as drugs, and finding new and efficient IDO inhibitors has important theoretical significance and application value

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of icarisid I type compound for preparing IDO inhibitor
  • Application of icarisid I type compound for preparing IDO inhibitor
  • Application of icarisid I type compound for preparing IDO inhibitor

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0027] Example 1: Effect of Icariside I on the Change of IFN-γ Content in T Cell Culture Supernatant

[0028] Prepare preparations for culturing cells according to conventional methods, recover and cultivate cells for experiments using conventional methods.

[0029] Collect freshly isolated or purchased CD3 + T cells were counted with a counting plate under an inverted microscope, seeded in a 96-well plate with 25,000 to 50,000 cells per well, and then added different concentrations of icariside Ⅰ prepared with medium and placed in a 5% CO 2 After cultured in the cell culture box for 48 hours, the supernatant of the cells was collected and stored in a freezer at -80°C, or the IFN-γ content secreted by T cells at different concentrations was detected directly with the IFN-γELISA kit, and calculated by GraphPad Prism 5 And plotted to get the effect of icariside Ⅰ on CD 3 at different concentrations + The effect of changes in the content of IFN-γ secreted by T cells, the result...

Embodiment 2

[0031] Example 2: Experimental procedures for the regulation of apoptotic protein expression by Western blot of icariin I

[0032] (1) Sample treatment: cells were seeded in a 96-well plate at a concentration of 5000 cells / well, 5 times the number of T cells were added to each well, and then different concentrations of icariside I diluted with medium were added to act Cells were collected after 48 hours and washed twice with PBS;

[0033] (2) Extraction of total protein: the liver cancer cells added to the plate were collected by centrifugation and washed twice with phosphate buffered saline. Add an appropriate amount of lysate to the cells, let stand on ice for half an hour, centrifuge at 12,000 rpm for 10 minutes in a refrigerated centrifuge, and transfer the supernatant to a new centrifuge tube. The BCA method is used to detect the protein concentration in the sample, add denaturing solution in a 95°C water bath for 8-10 minutes to denature the protein, and store it in a ref...

Embodiment 3

[0040] Example 3: Regulation of Icariside I on the Expression of Apoptotic Proteins

[0041] The Western blot experiment investigated the regulation of icariside Ⅰ on the expression of major apoptotic proteins in the IFN-γ-mediated apoptosis pathway in liver cancer cells at high concentrations of 8 μM and 32 μM. The results are as follows: figure 2 with image 3 shown.

[0042] figure 2 with image 3 It is the result of western blot experiment on liver cancer cells treated with 8 μM and 32 μM icariside Ⅰ for 48 hours in the presence of T cells. Here, the proteins related to the apoptosis cascade pathway (including PARP / cleaved PARP), as well as the marker proteins of apoptosis Noxa and Cytochrome C were mainly detected. The results showed that the expressions of apoptosis marker proteins Cytochrome C and cleaved PARP in HepG2 and Huh7 cells treated with icariside Ⅰ were significantly increased when the administration concentration was below 8 μM, and the expression of No...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides an application of an icarisid I type compound of formula I (shown in the specification) for preparing an IDO inhibitor. (The formula I is described in the specification). By study from the cellular level, the icarisid I can cause death of liver-cancer cells under the condition of existence of T cells, and proved from Western blot experiment, the icarisid I can regulate expression of main apoptosis protein in an IFN-gamma mediated apoptosis pathway in the liver-cancer cells under different concentrations. Results show that protein expression verifies the regulating effectof IFN-gamma, epimedium hormone can increase secretion of INF-gamma and enhance the own immunity of a human body. Further proved, the icarisid I can inhibit the activity of IDO obviously. In GAPDH antibody and IDO1 experiments, icarisid I can inhibit the activity of the IDO1 obviously and has no influence on the activity of the GAPDH antibody.

Description

technical field [0001] The present invention relates to the use of icariside I compound for preparing IDO inhibitors. Background technique [0002] Indoleamine 2,3-dioxygenase (IDO) is a heme-containing monomeric protein (promoting Fe +3 ion absorption), with superoxide anion as a cofactor, catalyzing the epoxidation and cracking of L-tryptophan indole, which is distributed in tissues other than the liver of humans and other mammals (lung, intestinal tract, placenta, epididymis, thymus, etc. ) and cells (macrophages, dendritic cells DC, monocytes, tumor cells and tumor-associated cells, eosinophils, etc.). [0003] IDO is the rate-limiting enzyme of tryptophan metabolism in the human body, and its activity is closely related to the function of immune T cells. Recent studies have found that in a variety of human malignant tumors, the expression of this enzyme is significantly enhanced, which reduces the immune function of the tumor site, which is one of the important reason...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/7048A61P35/00A61P37/06C07H17/07
CPCA61K31/7048A61P35/00A61P37/06C07H17/07
Inventor 郭晓路周金林卢宇靖黄宝华林丽薇李慧灵
Owner FOSHAN GOLDEN HEALTH TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com